{"id":"NCT03397134","sponsor":"Minerva Neurosciences","briefTitle":"Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia","officialTitle":"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Monotherapy, 12-Week Study to Evaluate the Efficacy and Safety of 2 Fixed Doses of MIN-101 in Adult Patients With Negative Symptoms of Schizophrenia, Followed by a 40-Week Open-Label Extension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-15","primaryCompletion":"2020-05-26","completion":"2021-02-15","firstPosted":"2018-01-11","resultsPosted":"2023-04-28","lastUpdate":"2023-04-28"},"enrollment":515,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Negative Symptoms of Schizophrenia"],"interventions":[{"type":"DRUG","name":"Placebo Oral Tablet","otherNames":[]},{"type":"DRUG","name":"Roluperidone 32 mg","otherNames":[]},{"type":"DRUG","name":"Roluperidone 64 mg","otherNames":[]}],"arms":[{"label":"Roluperidone 64 mg","type":"EXPERIMENTAL"},{"label":"Roluperidone 32 mg","type":"EXPERIMENTAL"},{"label":"Placebo-1","type":"PLACEBO_COMPARATOR"},{"label":"Placebo-2","type":"PLACEBO_COMPARATOR"}],"summary":"MIN-101C07 is a multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of roluperidone in adult schizophrenia patients.The primary objective is to evaluate the efficacy of 2 fixed doses of roluperidone compared to placebo in improving the negative symptoms of schizophrenia over 12 weeks of double-blind treatment as measured by the change in Positive and Negative Syndrome Scale (PANSS) Marder negative symptoms factor score (NSFS) over 12 weeks.","primaryOutcome":{"measure":"Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS)","timeFrame":"Baseline, Week 2, Week 4, Week 8, and Week 12","effectByArm":[{"arm":"Roluperidone 32 mg","deltaMin":25.2,"sd":3.43},{"arm":"Roluperidone 64 mg","deltaMin":25.3,"sd":3.26},{"arm":"Placebo","deltaMin":24.3,"sd":3.01}],"pValues":[{"comp":"OG001 vs OG002","p":"0.043"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":26},"locations":{"siteCount":39,"countries":["United States","Bulgaria","Poland","Ukraine"]},"refs":{"pmids":["35211743"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":59},"commonTop":["Headache","Insomnia","Schizophrenia","Asthenia","Agitation"]}}